The timing of puberty is controlled by many genes. The elements coordinating this process have not, however, been identified. Here we show that an epigenetic mechanism of transcriptional repression times the initiation of female puberty in rats. We identify silencers of the Polycomb group (PcG) as principal contributors to this mechanism and show that PcG proteins repress Kiss1, a puberty-activating gene. Hypothalamic expression of two key PcG genes, Eed and Cbx7, decreased and methylation of their promoters increased before puberty. Inhibiting DNA methylation blocked both events and resulted in pubertal failure. The pubertal increase in Kiss1 expression was accompanied by EED loss from the Kiss1 promoter and enrichment of histone H3 modifications associated with gene activation. Preventing the eviction of EED from the Kiss1 promoter disrupted pulsatile gonadotropin-releasing hormone release, delayed puberty and compromised fecundity. Our results identify epigenetic silencing as a mechanism underlying the neuroendocrine control of female puberty.
a r t I C l e S Much has been learned in recent years about the neuroendocrine mechanisms controlling the initiation of female reproductive function. It requires changes in the release of gonadotropin-releasing hormone (GnRH) from neurosecretory neurons mostly located in the medial basal hypothalamus of primates and in the preoptic region of rodents 1, 2 . These changes are, in turn, determined by modifications in trans-synaptic 3 and glial 4 inputs to the GnRH neuronal network. Whereas the trans-synaptic changes involve an increase in excitatory inputs and a reduction in inhibitory influences 1 , the glial component is predominantly facilitatory and is exerted by both growth factors and small molecules that directly or indirectly stimulate GnRH secretion 4 . The direct excitatory trans-synaptic regulation of GnRH secretion is provided by at least three different neuronal subsets: kisspeptin neurons acting via the G protein-coupled receptor KISS1R (also known as GPR54) 5 , glutamatergic neurons acting mostly via AMPA receptors 6, 7 but also via NMDA receptors 7, 8 , and GABA acting via ionotropic GABA A receptors 9 . The inhibitory counterpart of this circuitry depends principally on GABAergic neurons acting via GABA B metabotropic receptors 9 but also on opiatergic neurons that employ different peptides and a variety of different receptors for inhibitory neurotransmission (reviewed in ref. 1) .
As predicted by the complexity of this cellular network, several reports have suggested that no isolated pathway or cellular subset is solely responsible for the neuroendocrine control of puberty [10] [11] [12] . Instead, initiation of this process may require regulatory gene networks controlled by a handful of upstream genes 10 . Some of these central nodes have been identified, including the POU-domain gene Pou2f2 (also known as Oct2), the homeodomain gene Nkx2-1 (Ttf-1)), and a zinc finger-containing gene termed Irf2bpl (interferon regulatory factor 2 binding protein-like; also known as Eap1, for Enhanced At Puberty 1) 13 . Although monogenic mutations such as those affecting GNRHR 14 , KISS1R (GPR54) 15, 16 , KISS1 (ref. 17) , TAC3 and TACR3 (ref. 18 ) result in pubertal failure, it does not appear that these are the only puberty-relevant genes, as genome-wide association studies have shown that variants of more than 30 genes are associated with the age of menarche in humans 19 .
It is thus apparent that the genetic underpinnings of puberty are multigenic, but this realization does not explain how inherited, permanent changes in DNA sequence can regulate gene expression dynamically while also imposing an encompassing level of coordination and transcriptional plasticity on the gene networks involved. Here we develop the concept that a biological regulatory system that meets these requirements is epigenetics. Our results provide proof of principle for the view that the timing of female puberty is under the regulatory control of an epigenetic mechanism of transcriptional repression. We identify the Polycomb group (PcG) of transcriptional silencers 20 as integral parts of this repressive mechanism and implicate two PcG genes (Cbx7 and Eed) as encoding core components of the PcG complex operating in the prepubertal hypothalamus. Using the Kiss1 gene as a prototype of a gene whose products are directly involved in controlling GnRH output 21 , we provide evidence that the PcG complex represses the advent of reproductive maturity by targeting downstream genes involved in the stimulatory control of GnRH secretion at puberty.
RESULTS

Inhibition of DNA methylation results in pubertal failure
To gain insights into the potential contribution of DNA methylation to the regulation of puberty, we inhibited DNA methylation by treatment with 5-azacytidine (Aza), a well-established DNA methyltransferase a r t I C l e S (DNMT) inhibitor 22, 23 . The treatment (2 mg per kilogram body weight per day, intraperitoneally) was initiated on postnatal day (P) 22, which in the rat corresponds to the initiation of the early juvenile phase of pubertal development 2 . We first evaluated the effect of Aza on the timing of puberty and estrous cyclicity by continuing the treatment until P44; that is, nearly 2 weeks after all control rats (injected with saline solution) had reached puberty. In all subsequent studies, the rats were treated only for the duration of the juvenile period; that is, from P22 to P28. Rats subjected to long-term Aza treatment had delayed vaginal opening ( Fig. 1a ; mean age at vaginal opening: control, 31.33 ± 0.21 d, n = 6; versus Aza, 36.67 ± 0.67 d; t = -7.628, P < 0.001, Student's t test); failed to reach puberty, as assessed by the lack of ovulation; and showed no estrous cyclicity, as determined by daily vaginal lavages after vaginal opening (Fig. 1b) . These alterations did not appear to result from a nonspecific effect of Aza, because the rats treated with the inhibitor weighed substantially more (20 g) than control rats at the time of vaginal opening and had not achieved puberty by the end of the experiment even though they weighed 35 g more than the weight reached by controls at the time of first ovulation ( Supplementary  Fig. 1 ). Morphological examination either at P28, which marks the transition between late juvenile development and the initiation of puberty 2 , or on P44 showed that the ovaries of Aza-treated rats had no overt abnormalities but were developmentally delayed ( Fig. 1c) . By P28, these ovaries had only small antral follicles and were about half the size of a control ovary. At P44, the ovaries of Aza-treated rats had antral follicles but no corpora lutea, indicating that they had not ovulated and, consequently, that puberty had failed to occur.
To determine where Aza may be acting to prevent the advent of puberty, we first examined the competence of the ovary to respond to gonadotropins with estradiol production. We treated rats with Aza from P22 to P28, administered a single subcutaneous injection of pregnant mare serum gonadotropin (PMSG, 8 IU per rat) on P26 and collected trunk blood for estradiol measurement on P28. The Aza treatment did not inhibit, and even enhanced, the estradiol response of the ovary to PMSG ( Fig. 2a) . This outcome suggested that the delay in puberty was due to a central or pituitary, instead of an ovarian, defect. Consistent with this interpretation, basal plasma luteinizing hormone was lower in P28 Aza-treated rats than vehicle-treated controls (control, 1.89 ± 0.41 ng ml −1 , n = 19; versus Aza, 0.55 ± 0.16 ng ml −1 , n = 23; t = 3.23, P = 0.002, Student's t test), and Aza-treated rats had a greatly diminished luteinizing hormone response to ovariectomy, performed on P24 and assessed on P28 (control, 52.56 ± 6.93 ng ml −1 , n = 6; versus Aza, 7.43 ± 2.76 ng ml −1 , n = 6; t = 6.48, P < 0.001, Student's t test). Despite this deficiency, the pituitary response to in vivo administration of GnRH on P28 was normal in Aza-treated rats ( Fig. 2b) , indicating the absence of a pituitary defect. To evaluate the ability of GnRH neurons to respond to a physiological neuroendocrine stimulus, we exposed medial basal hypothalamic (MBH) fragments from P28 rats, which contain the median eminence-arcuate nucleus (ME-ARC) region, to kisspeptin, a potent GnRH secretagogue 24 . The ME-ARC from Aza-treated rats responded to kisspeptin with significantly more GnRH release than vehicle-treated controls ( Fig. 2c ), suggesting cellular hyper-responsiveness presumably due to a deficiency in endogenous kisspeptin production. a r t I C l e S Because these results implied a hypothalamic site of Aza action, we carried out a study to verify the ability of Aza to reduce DNA methylation in the hypothalamus. We measure global DNA methylation in the MBH and cerebral cortex at two intervals (1 and 7 d) after starting Aza treatment. At both time points, DNA methylation was significantly reduced in the MBH but not the cerebral cortex ( Fig. 2d) . This difference may be due to the lack of a fully functional blood-brain barrier in the MBH, a feature that allows transfer of macromolecules from the bloodstream to the hypothalamic parenchyma 25, 26 .
To determine whether Aza may have delayed puberty by affecting hormonal systems other than that controlling the hypothalamicpituitary-ovarian axis, we measured serum prolactin (PRL) because PRL is produced independently from luteinizing hormone, delays puberty when secreted at subnormal levels and disrupts estrus cyclicity when produced in excess 2 . We found that serum PRL measurements were identical in diluent-and Aza-treated rats (control, 1.9 ± 0.4 ng ml −1 , n = 8; versus Aza, 1.8 ± 0.3 ng ml −1 , n = 7; t = 0.433, P = 0.67, Student's t test). To examine yet another endocrine system, we measured serum corticosterone, an adrenal steroid known to delay the onset of puberty in rats when secreted in excess in response to stress 2 . Instead of being elevated, corticosterone levels were reduced in Aza-treated rats (control, 232.8 ± 49.5 ng ml −1 , n = 7; versus Aza, 47.1 ± 11.8 ng ml −1 , n = 7; t = 9.66, P < 0.001, Student's t test), possibly owing to a diminished ovarian estradiol output 27 . Thus, the delay of puberty caused by Aza treatment is not due to either deregulation of PRL secretion or to corticosterone hypersecretion. Altogether, these results suggest that inhibition of DNA methylation delays puberty by unleashing a repressive mechanism that, operating in the neuroendocrine brain, keeps puberty in check by inhibiting genes (such as Kiss1) required for puberty to occur.
A repressive complex is silenced at puberty To search for potential repressor genes that may become more methylated in the hypothalamus at puberty, we used DNA methylation arrays to interrogate the MBH at different pubertal stages (early juvenile, late juvenile and late proestrus). The late proestrus phase of puberty corresponds to the day of the first preovulatory surge of gonadotropins, which in the rat can be considered as mid-puberty 2 . We observed (see Supplementary Fig. 3 ) that genes with a pattern of changing methylation at either the late juvenile or late proestrus phases of puberty were functionally enriched for a cluster of chromatin/histone modification terms. Several of these genes are components of a common regulatory pathway as they were either members of the PcG silencing complex (Cbx7, Cbx8, Phc3, Yy1 and Rnf2 (also known as Ring1B)) or encoded proteins that interact with PcG proteins (Rybp, Csnk2b, Kdm2b). With the exception of Rnf2, all of these genes exhibited a general pattern of Figure 2 In vivo inhibition of DNA methylation prevents puberty by disrupting developmental events upstream from the GnRH-pituitaryovarian axis. (a) Treatment with Aza in fact augments the estradiol response of the ovary to stimulation with PMSG (F 3,31 = 47.81, P < 0.001, one-way ANOVA followed by Student-Newman-Keuls (SNK) multiple comparison test, n = 8 rats per group). (b) GnRH (6.5 µg kg -1 intraperitoneally) injection increases plasma luteinizing hormone (LH) similarly in vehicle-treated control and Aza-treated rats (between time points within each treatment, F 2,7 = 277.23, P < 0.001, but between treatments, F 1,7 = 0.46, P = 0.52, with no significant interaction between time points and treatments, F 2,47 = 0.56, P = 0.58, two-way repeated-measures ANOVA, n = 8 rats per group). (c) Hyper-response of the GnRH system to kisspeptin, as determined by the in vitro release of GnRH from ME-ARC fragments (derived from P28 rats) incubated with either 100 or 500 nM of the 10-amino-acid peptide kisspeptin-10 (Kp) (interaction between treatment group and Kp dose, F 3,47 = 5.93, P = 0.007, two-way repeated-measures ANOVA, n = 6 rats per group). (d) Aza treatment reduces global DNA methylation in the female rat hypothalamus but not in the cerebral cortex (CTX) as compared with diluent-treated controls (in MBH: 1 d of treatment t = 3.65, P = 0.004; 7 d of treatment t = 2.98, P = 0.044; in CTX: 1 d t = 0.803, P = 0.441; 7 d t = -0.928, P = 0.375; Student's t test, n = 6 rats per group). Means ± s.e.m. throughout. *P < 0.05; **P < 0.01; ***P < 0.001. Supplementary Fig. 2 ), suggesting that the PcG silencing complex may undergo functionally important epigenetic changes with the advent of puberty.
The PcG silencing complex is considered a master regulator of genomic programs because it acts at different stages of development to define which sets of genes are active and which ones are quiescent 20,28 . The PcG system is composed of three repressive complexes (PRC1, PRC2 and PhoRC) working together to silence genes 20, 28 . The PRC1 complex ( Supplementary Fig. 3 ) includes a group of proteins termed CBX because they contain a highly conserved chromodomain (CBX) at their amino terminus 29 . The mammalian homologs of Drosophila polycomb proteins are CBX2, CBX4, CBX6, CBX7 and CBX8 (ref. 28 ). In different cells, the PRC1 complex may contain different CBX proteins 30 . The PRC2 complex includes four core subunits: enhancer of Zeste (EZH1, EZH2), suppressor of Zeste (SUZ12) and the WD40 domain proteins EED and P55 (RBBP4 and RBBP7) 28 (Supplementary  Fig. 3) . PhoRC, the third PcG complex in Drosophila, contains two proteins, Pho and its homolog Phol, which bind directly to DNA 28 . In mammals, these proteins are encoded by the Yy1 gene ( Supplementary  Fig. 3 ), which has both repressive and activating functions 31 .
To determine whether the changes in promoter DNA methylation of PcG genes suggested by the arrays are accompanied by altered gene expression, we focused our attention on the PcG complex and measured by quantitative (q) PCR the mRNA abundance of most members of this complex in the MBH at the time of puberty. Expression of only two PcG genes required for appropriate PcG function 29, 32 , the PRC1 member Cbx7 and the PRC2 member Eed (not represented in the DNA arrays), decreased at the late juvenile stage; that is, at the time when puberty is initiated in the female rat 2 . This reduction was maintained throughout puberty ( Fig. 3a) , seemingly unaffected by the peripubertal increase in serum estradiol (Fig. 3b) , but was prevented by the administration of Aza (Fig. 3a) . Among the other members of the PcG complex examined, only Yy1 mRNA decreased significantly (P < 0.05) at puberty, but this decrease occurred much more gradually (Supplementary Fig. 3 ). No reduction in mRNA of any member of the PcG complex, including Cbx7 and Eed, was seen in the preoptic area during puberty ( Supplementary Fig. 3) , indicating that the pubertal decrease in Cbx7 and Eed expression was MBH-specific.
The advent of puberty was associated with increased promoter methylation of both Cbx7 and Eed (Fig. 3c) , and this change was prevented by Aza ( Fig. 3c) . The regions examined for changes in a r t I C l e S methylation are shown in Supplementary Figure 4 . The increase in DNA methylation did not result from changes in circulating estradiol amounts, because it was distinct at late juvenile, when plasma estradiol is still low, and remained unabated on the day of the first preovulatory surge of gonadotropins ( Fig. 3c) , when plasma estradiol is much higher (Fig. 3b) . Altogether, these results suggest that the onset of female puberty is accompanied by active epigenetic repression of the PcG silencing system in the MBH of female rats.
The Kiss1 gene is a downstream target of PcG repression In all mammalian species so far studied, the first neuroendocrine manifestation of puberty is a diurnal increase in pulsatile GnRH and hence luteinizing hormone release (reviewed in ref.
2). This mode of GnRH secretion has been postulated to be driven by a subset of ARC neurons, called KNDy neurons 33, 34 because they produce kisspeptin, NKB and dynorphin 33 . Because kisspeptin and NKB work coordinately in the population of KNDy neurons to stimulate GnRH secretion, their encoding genes (Kiss1 and Tac2) can be considered components of a distinct class of puberty-activating genes.
Using Kiss1 as a prototype of this class, we carried out studies to determine whether Cbx7 and Eed are expressed in kisspeptin neurons of the ARC. Double fluorescence in situ hybridization ( Fig. 4a ) and single-cell PCR (Fig. 4b) of eGFP-tagged mouse kisspeptin neurons 35 showed that these neurons contained both Eed and Cbx7 mRNAs. Measurement of the mRNAs encoding kisspeptin and its receptor KISS1R in the MBH demonstrated that Kiss1 mRNA abundance increased in this brain region between early juvenile and late juvenile stages and that inhibition of DNA methylation prevented this change (Fig. 5a) . In contrast, Kiss1r mRNA abundance remained unaltered in late juvenile rats as compared with early juvenile but was significantly increased by the inhibition of DNA methylation (Fig. 5b) . These results suggest that the hyper-responsiveness of the GnRH neuronal network to kisspeptin seen in Aza-treated rats may be related, at least in part, to a reduced endogenous production of kisspeptin in the presence of upregulation of its receptor KISS1R. Methylation of the Kiss1 promoter remained unchanged in the MBH of late juvenile rats as compared with early juvenile (Fig. 5c) , indicating that the increase in Kiss1 mRNA observed at the end of juvenile development is not caused by alterations in promoter methylation. Although Aza decreased Kiss1 promoter methylation ( Fig. 5c) , it obliterated the pubertal increase in Kiss1 mRNA, suggesting that inhibition of DNA methylation prevents the pubertal increase in Kiss1 expression by mechanisms other than changes in Kiss1 promoter methylation.
Because MBH expression of both Cbx7 and Eed appeared to be DNA methylation dependent and because EED is essential for PcG action 32 , we selected Eed for further analysis. In silico analysis of the Kiss1 promoter ( Supplementary Fig. 5a ) demonstrated that it contained several motifs found to be present in PcG target genes, including the core motif for YY1 binding (CCAT), the GAF (GAGAG) and extended MPho (CNGCCATNDNND) motifs 36 , two BMI1 binding motifs (CCTTCC and GGNNNGNG) previously reported 37 , and the binding motif for HOTAIR, a long noncoding RNA, recently shown to serve as an anchor for PcG binding to gene promoters 38 . To determine whether these motifs have biological significance, we performed gene promoter assays. EED indeed repressed Kiss1 promoter activity, and this repressive effect was enhanced by YY1 ( Supplementary Fig. 5b ). Next, we carried out chromatin immunoprecipitation (ChIP) assays to determine (i) whether EED is recruited to the Kiss1 promoter in the MBH and (ii) whether this relationship changes during the onset of puberty. EED protein was associated with the Kiss1 promoter at the early juvenile stage, and this association decreased at the late juvenile stage, the time of initiation of puberty (Fig. 5d) . Consistent with the notion that inhibition of DNA methylation leads to increased expression of PcG genes, which then repress downstream targets genes, the pubertal loss of EED association to the Kiss1 promoter did not occur in Aza-treated rats (Fig. 5d) . The chromatin status of the Kiss1 promoter also changed at the time of puberty. Whereas the content of histone H3 trimethylated on Lys27 (H3K27me3), a PcG-dependent repressive histone modification 39, 40 , did not decrease significantly in late juvenile rats (Fig. 5e) , the abundance of two activating histone H3 modifications, trimethylation on Lys4 (H3K4me3) and acetylation on Lys9 and Lys14 (H3K9,14ac) 39, 41, 42 , increased markedly at this time ( Fig. 5f,g) . Treatment with Aza, which prevented the eviction of EED from the Kiss1 promoter at the late juvenile stage, also prevented the late juvenile increase in both H3K4me3 and H3K9,14ac abundance ( Fig. 5f,g) .
To determine whether the chromatin landscape of the Kiss1 promoter continues to change as the pubertal process unfolds, we measured both H3K27me3 and its opposing counterpart H3K4me3 (ref. 43) at late proestrus, when the preovulatory surge of gonadotropins take place, and found a significant (P < 0.05) decrease in H3K27me3, Fig. 6a ). Altogether, these results are compatible with the notion that a repressive PcG-dependent influence on the Kiss1 gene is lifted at the onset of puberty and the status of the associated chromatin shifts from an inhibitory to an activating configuration, leading to activation of the Kiss1 gene ( Supplementary Fig. 6b ).
Overexpressing EED compromises reproductive capacity
If PcG proteins influence neuroendocrine control of female puberty by repressing the Kiss1 gene in the ARC, then preventing the pubertal decrease in PcG gene expression that occurs in this hypothalamic region at the onset of puberty would be expected to delay puberty. Because Eed is required for the silencing activity of the PcG complex 32 , we chose to overexpress EED in the ARC of immature female rats. We cloned the coding region of rat Eed tagged with a hemagglutinin (HA) epitope into a lentiviral vector (LV) that also expresses eGFP (Supplementary Fig. 7a) . After confirming the production of the HA-tagged protein by western blot (Supplementary Fig. 7b ), we stereotaxically delivered this construct (termed LV-EED) bilaterally into the hypothalamus of P26 female rats, targeting the ARC. Control rats were injected with a construct expressing only eGFP (LV-eGFP).
We used immunohistofluorescence analysis of the sites of injection using antibodies to eGFP to identify the transduced cells ( Fig. 6a) .
Kisspeptin neurons, also identified by immunohistofluorescence, were one of the cell populations transduced by the virus (Fig. 6b,c) . ChIP analysis of DNA extracted from microdissected ARC tissue containing the transduced cells revealed that the LV-produced EED-HA protein had been recruited to the Kiss1 promoter (Fig. 6d) . The number of detectable immunopositive kisspeptin cells per section decreased 25% in LV-EED-injected rats (LV-GFP, 21.4 ± 1.98, n = 31;
versus LV-EED = 15.9 ± 1.22, n = 6; t = 3.65, P < 0.001, Student's t test), and the abundance of kisspeptin immunoreactive material per cell was reduced by 30% in LV-EED-injected rats as compared to control rats injected with LV-GFP (LV-GFP, 141.4 ± 1.89 arbitrary units (AU), n = 102; versus LV-EED, 95.2 ± 2.7 AU, n = 94; t = 14.35, P < 0.001, Student's t test) ( Fig. 6e) , indicating that EED overexpression compromised kisspeptin production in about 50% of the ARC population of kisspeptin neurons. This inhibition is consistent with our in vitro results showing a repressive effect of EED on Kiss1 promoter activity (Supplementary Fig. 5b) .
To determine whether overexpression of EED alters pulsatile GnRH release from the hypothalamus, we delivered LV-EED or LV-GFP to the ARC of a group of P22 female rats, dissected the ME-ARC region 7 d later and incubated the tissues for 3 h in Krebs-Ringer bicarbonate buffer, sampling the medium every 7.5 min, to measure GnRH output 44 . The ME-ARC of rats injected with LV-GFP showed a robust pattern of pulsatile GnRH release, with episodes of secretion occurring every 41 ± 2.7 min (Fig. 7a,b) . In contrast, GnRH pulse frequency was reduced (P < 0.05; Mann-Whitney rank-sum test) to one pulse every 98 ± 30.7 min in LV-EED-injected rats (Fig. 7a,b) . GnRH pulse amplitude was not affected (Fig. 7b) , but total GnRH output was reduced in the LV-EED-treated group (Fig. 7b) . Measurement of Eed and Kiss1 mRNAs at the end of the incubation demonstrated that the ME-ARC of rats receiving LV-EED had four times more Eed mRNA than the ME-ARC of rats injected with LV-GFP (Fig. 7c) , and that-as consistent with the immunohistochemistry data-Kiss1 mRNA was reduced by 50% ( Fig. 7c) .
In keeping with these observations, a further experiment showed that the age at first ovulation, assessed by the detection in vaginal smears of cornified cells (first estrus) followed by 2 consecutive days of leukocytes (a condition highly correlated with ovulation) was delayed several days in LV-EED-injected rats (age at first ovulation: LV-GFP, 33 ± 0.31 d, n = 5; versus LV-EED, 37.8 ± 0.6 d, n = 6; t = -16.12, P < 0.001, Student's t test), and estrous cyclicity was disrupted (Fig. 8a,b) . Examination of the ovaries at P50 showed that LV-EED-injected rats had some corpora lutea, indicating that they had ovulated, but also exhibited an excess of antral follicles that had not npg a r t I C l e S reached the periovulatory stage (Fig. 8c) . In contrast, LV-GFP-injected rats had an abundance of corpora lutea, indicating repeated ovulations (Fig. 8c) . In a third experiment, we delivered the LV-GFP and LV-EED constructs to the ARC of P22 rats and, after all rats in the LV-GFPinjected group showed three complete estrous cycles, exposed each rat to a fertile male for 5 d. Rats in which the LV-EED construct was correctly targeted to the ARC had fewer pups or failed to deliver a litter on exposure to a fertile male ( Supplementary Table 3 ), in comparison to the >90% fertility observed in LV-GFP-injected controls (Fig. 8d) .
Thus, preventing the reduction in Eed expression that occurs in the ARC at the onset of puberty compromises GnRH pulsatile release, delays the pubertal process, disrupts estrous cyclicity, reduces ovulation and decreases fecundity. Altogether, these results are consistent with the interpretation that the onset of female puberty is controlled by a PcG-dependent repressive mechanism involving silencing of the Kiss1 gene in kisspeptin neurons of the MBH.
DISCUSSION
The potential contribution of epigenetics to the regulation of puberty has, to our knowledge, never been addressed. In the present report, we provide evidence that an epigenetic mechanism of transcriptional repression, operating in the neuroendocrine brain, influences the timing of female puberty. Our results identify the PcG system of transcriptional silencing 20,28 as a central element of this repressive mechanism. Hypothalamic expression of Cbx7 and Eed, two PcG genes required for PcG action 29, 32 , decreased before the onset of puberty, and this change was associated with increased DNA methylation of their 5′ flanking regions. Conversely, pharmacological inhibition of DNA methylation prevented the pubertal increase in Eed and Cbx7 DNA methylation, reversed the low peripubertal Eed and Cbx7 mRNA levels to elevated early-juvenile values, and delayed puberty. This delay was not due to a nonspecific or toxic effect of the inhibitor, because the rats failed to reach puberty despite a body weight much greater than that attained by control rats at puberty. Moreover, it was not caused by changes in the secretion of two hormones, PRL and corticosterone, that in deficiency (PRL) or excess (corticosterone) have been shown to delay puberty in the rat (reviewed in ref.
2). Within the hypothalamic-pituitary-ovarian axis, inhibition of DNA methylation did not affect the capacity of the ovary to respond to gonadotropin stimulation with estrogen release and did not alter the pituitary gonadotropin response to GnRH, suggesting a central site of action. Direct assessment of the GnRH response to kisspeptin, a principal GnRH secretagogue 24 , revealed that GnRH neurons of Aza-treated rats were hyper-responsive, instead of unresponsive, to kisspeptin. Although Aza, like other DNMT inhibitors, may also act through mechanisms other than DNA methylation 45, 46 , our results are consistent with the interpretation that pharmacological inhibition of DNA methylation prevents a methylation event scheduled to occur at the onset of puberty. Without ruling out GnRH neurons as direct targets of epigenetic control 47 , our results suggest that (i) the pubertal delay caused by inhibition of DNA methylation involves cellular subsets functionally connected to the GnRH neuronal network and that (ii) the deficit may result from the activation of repressive genes whose expression would normally decrease at puberty. By inference, these repressors would be expected to negatively control the expression of downstream genes that must be activated for puberty to occur.
A search for such repressors using DNA methylation arrays suggested that the initiation of puberty was accompanied by changing methylation of the promoters of several members of the PcG repressive complex and genes encoding proteins that interact with the PcG system. If this change predicts opposite changes in gene expression, one would expect to find decreased hypothalamic expression of PcG genes either during puberty or immediately before it. Measuring the expression of most PcG components in the MBH by qPCR demonstrated an early decrease in Cbx7 and Eed mRNA abundance before the initiation of puberty and a drop in Yy1 expression at mid-puberty. EED is a PRC2 component required for PcG action 32 . The decrease in Cbx7 and Eed expression occurred independently from changes in ovarian estrogen output, as it was essentially complete before the pubertal increase in circulating estrogen. Rat 2 30 32 34 36 38 Age (d) 40 42 44 46 48 Rat 4
Rat 4 30 32 34 36 38 Age (d) 40 42 44 46 48 Rat 5
Rat 5 30 32 34 36 38 Age (d) 40 36 38 Age (d) 40 npg a r t I C l e S Because the kisspeptin-KISS1R system is critical for both puberty and adult reproductive function 15, 16 , the Kiss1 gene can be considered a prototype of the class of genes that need to be activated for puberty to occur. Accordingly, we used the Kiss1 gene to test the hypothesis that these puberty-activating genes may be subjected to PcG repressive control. The increase in Kiss1 mRNA abundance that occurs in the hypothalamus at the time of puberty was prevented, instead of enhanced, by inhibition of DNA methylation, suggesting that a secondary mechanism set in motion by the loss of DNA methylation is responsible for the reduction in Kiss1 expression. A notable component of this mechanism appears to be the PcG silencing complex, as the prepubertal association of EED to the Kiss1 promoter, which diminished at the onset of puberty, was prevented by inhibition of DNA methylation.
PcG-mediated gene silencing requires H3K27me3, a modification catalyzed by PRC2. H3K27me3 then provides a docking site for the CBX components of PRC1 to form a repressive complex 20, 28 . In turn, YY1 recruits PRC2 and PRC1 proteins, in addition to H3K27me3, to gene promoters to enhance transcriptional silencing 32 . The eviction of EED from the Kiss1 promoter at the onset of the pubertal process would predict a concomitant loss of H3K27me3 at this time. Instead, H3K27me3 content decreased at late proestrus; that is, by mid-puberty. Contrasting with this protracted pattern of change, the abundance of H3K4me3 and H3K9/14ac, two histone marks associated with gene activation 39, 41 , increased markedly at the late juvenile stage; that is, at the initiation of puberty. Because H3K4me3 is a histone mark that opposes the repressive actions of H3K27me3 (ref. 43) , we examined the association of H3K4me3 to the Kiss1 promoter at mid-puberty and found it to remain as elevated as at the late juvenile stage. This developmental profile is consistent with the pattern of bivalent association observed for H3K27me3 and H3K4me3 in the promoters of genes mildly derepressed during development 48 . The evolving presence of both marks on the Kiss1 promoter at puberty is also consistent with the concept of "bivalent" domains 48 ; that is, the simultaneous presence of repressive and activating histone modifications 48, 49 in the regulatory regions of genes thought to be poised for activation in response to developmental cues 50 . Notably, the pubertal increase in the association of activating histone marks to the Kiss1 promoter failed to occur in Aza-treated rats. Because the pubertal EED eviction also fails to occur in these animals, the simplest explanation is that persistent EED occupancy diminishes accessibility of activating histone marks to the Kiss1 promoter.
Directly supporting the overall validity of a PcG-dependent repressive mechanism holding in check the initiation of puberty is the pubertal delay observed when the decline in hypothalamic Eed expression that occurs during normal puberty is prevented by means of targeted lentivirus-mediated gene delivery. Overexpression of Eed in the ARC of the hypothalamus, which contains the KNDy neurons required for pulsatile GnRH release 34 , reduced the number of neurons expressing detectable immunoreactive kisspeptin, the content of immunoreactive kisspeptin per cell and the abundance of Kiss1 mRNA in the ARC. And notably, it reduced pulsatile GnRH release, delayed puberty, and disrupted estrous cyclicity. Although the rats receiving lentiviral particles carrying the EED gene were still able to ovulate, their estrus cycle profiles suggested that they were ovulating sporadically. This inference is supported by the finding that these females delivered an average of 2 pups when exposed to a fertile male, as compared with 12 pups delivered by rats receiving either a control virus or a virus expressing EED but targeted outside the ARC.
By showing that the neuroendocrine control of female puberty involves the participation of a repressive mechanism of epigenetic regulation, our results provide insight into the integrative mechanisms used by the neuroendocrine brain to control the initiation of mammalian puberty. As such, they are consistent with the concept that the pubertal process depends not only on genetic determinants, but also on developmentally regulated changes in epigenetic information. They also raise the possibility that human syndromes of idiopathic precocious and delayed puberty of central origin may have a previously unappreciated epigenetic component.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. GEO: GSE38505.
Note: Supplementary information is available in the online version of the paper.
ONLINE METHODS
Animals. Rats. The use of rats (Sprague Dawley, Charles River Laboratories) was approved by the Oregon National Primate Research Center (ONPRC) Animal Care and Use Committee in accordance with the National Institutes of Health (NIH) guidelines for the use of animals in research. The rats were housed in a room with controlled photoperiod (14/10 h light/dark cycle) and temperature (23-25 °C) and were allowed ad libitum access to tap water and pelleted rat chow.
To inhibit DNA methylation we treated rats with 5-azacytidine (Aza; 2 mg kg -1 d -1 , i.p.), starting on postnatal day (P) 22. Control animals received the vehicle (saline solution, 2 ml kg -1 ). Some animals were treated for 3 weeks to assess the time of puberty and estrous cyclicity. In all other studies, the animals were treated with Aza from P22 to P28.
To assess the estradiol response of the ovary to gonadotropins, immature control and Aza-treated rats were administered pregnant mare serum gonadotropin (PMSG; single s.c. injection, 8 IU per rat) at P26, and trunk blood was collected 2 d later for measurement of serum estradiol. The pituitary LH response to GnRH was assessed by injecting the decapeptide (Sigma Aldrich, St. Louis, MO; 6.5 µg -1 kg; i.p.) and measuring LH in blood samples drawn 15 and 60 min later.
To determine whether overexpressing EED in the arcuate nucleus (ARC) of the hypothalamus would affect kisspeptin production, pulsatile GnRH release, the timing of puberty, estrous cyclicity and fecundity, female rats received on P22 an intrahypothalamic injection of lentiviral particles targeting EED to the ARC (details below). Some animals were killed 2 weeks after vaginal opening, and the number of immunopositive kisspeptin cells and the content of kisspeptin per cell in the ARC were assessed by immunohistofluorescence. Other animals were injected with the viral particles on P22, exposed to a fertile male for 5 d after all control (LV-GFP)-injected rats had undergone three complete estrous cycles, and their ability to deliver a litter evaluated. In a third experiment, the animals received the viral construct on P22, and pulsatile GnRH release from hypothalamic fragments containing the median eminence (ME)-ARC region was examined in vitro on P28.
Animals were randomly assigned to each treatment group.
Mice. Female mice expressing enhanced green fluorescent protein (GFP) under the control of the 5′ flanking region of the mouse Kiss1 gene 35 were bred and housed at the Oregon Heath and Sciences University (OHSU). All procedures performed using these animals were in accordance with the NIH Guide for the Care and Use of Laboratory Animals and were approved by the OHSU Animal Care and Use Committee. ovariectomy. Ovariectomy (OVX) of rats was performed at P24 under isoflurane anesthesia, and trunk blood was collected 96 h later for serum LH measurement. Ovariectomy of mice was similarly performed. All animals were given carprofen as an analgesic (4 mg kg -1 ) before surgery. evaluation of sexual maturation and adult reproductive function. Rats were killed at four different peripubertal stages defined according to previously established criteria 2 : EJ: early juvenile (21 d of age), LJ: late juvenile (28 d of age), EP: early proestrus (30-35 d of age) and LP: late proestrus (32-37 d of age). Animals in LJ exhibit a diurnal change in pulsatile plasma LH levels, with the LH pulses becoming more pronounced in the afternoons 2 . This change is considered to be the first neuroendocrine manifestation of puberty 2 . The first ovulation occurs the day after LP.
Once vaginal opening occurred, vaginal lavages were performed daily to identify the occurrence of the first estrus, which in rodents is manifested by a predominance of cornified cells. The age at first ovulation was considered to have occurred only when the cornified cells were followed by at least 2 d of lavages containing mostly leukocytes.
Trunk blood was collected on P28 for measurement of circulating LH, prolactin and corticosterone. At both P28 and P44, the ovaries were fixed in Kahle's fixative, embedded in paraffin, serially sectioned at 6 µm, stained with Weigert's iron hematoxylin and counterstained with picric acid-methyl blue for morphological evaluation.
Groups of animals receiving intrahypothalamic injections of lentiviral particles were killed at either P44 or after verifying their ability (or lack thereof) to deliver a litter when exposed to a fertile male, and their brains were perfusion-fixed for immunohistochemical verification of the site of injection (see below).
Incubation of me and ARc-me explants and measurement of gnRH release.
Median eminence explants from rats treated for 7 d with either Aza or vehicle were incubated in vitro for 1 h under basal conditions and then for 1h in the presence of 100 nM kisspeptin 110-119 (Phoenix Pharmaceuticals, Burlingame, CA). After another 1-h period of basal release, the tissues were stimulated for 1 h with 500 nM kisspeptin. GnRH released to the incubation medium was determined by RIA.
To estimate changes in pulsatile GnRH release from the ME-ARC of rats in which EED was overexpressed in the ARC via stereotaxic delivery of an EEDexpressing LV construct, we used P28 rats that had received the LV construct on P22. The ME-ARC from animals receiving either LV-EED or LV-GFP was placed in Krebs-Ringer bicarbonate buffer and incubated for 4 h, removing the medium every 7.5 min for GnRH measurement 51 . GnRH pulses were analyzed as described 51 .
measurement of gnRH, serum lH, estradiol, PRl and corticosterone levels.
Assays for serum LH, prolactin (PRL), estradiol , corticosterone and gonadotropin-releasing hormone (GnRH) were performed by the Endocrine Technology and Support Lab, Oregon National Primate Research Center (Beaverton, OR).
RnA and dnA extraction. Total RNA and DNA were extracted using the AllPrep DNA/RNA Mini kit (Qiagen, Valencia, CA), according to the manufacturer's protocol.
Reverse transcription-PcR. Total RNA (500 ng) was transcribed into cDNA in a volume of 20 µl using 4 U Omniscript reverse transcriptase (Qiagen), and PCRs were performed using 1 µl of each reverse transcription reaction and SybrGreen ER (Invitrogen, Carlsbad, CA) in a volume of 10 µl. Ribosomal 18S RNA was measured in each sample as a housekeeping gene. Accession numbers of the genes amplified and primers sequences are shown in Supplementary Table 1. global dnA methylation. Global DNA methylation was determined in individual hypothalami using the Methylamp Global DNA Methylation Quantification Kit (Epigentek, Brooklyn, NY) according to the manufacturer's protocol. methylcytosine enrichment and quantification of dnA methylation. Methylated DNA was enriched using the EpiQuik Methylated DNA Immunoprecipitation Kit (Epigentek), following the procedure recommended by the manufacturer. For methylation array analysis, IP and input samples were amplified using the GenomePlex Complete Whole Genome Amplification (WGA2) Kit (Sigma) also following the manufacturer's instructions.
DNA methylation arrays. Immunoprecipitated and input samples were labeled with Cy5 and Cy3 respectively and hybridized to a Rat DNA Methylation 3x720K CpG Island Plus RefSeq Promoter Array (NimbleGen-Roche, Indianapolis, IN). The array procedure, scanning and data extraction were performed by the Center for Genome Research & Biocomputing at the Oregon State University. Methylation profiles were viewed using the NimbleGen SignalMap data browser.
Targeted DNA methylation-qPCR analysis. Validation of the DNA methylation arrays results was performed using a SybrGreen ER (Invitrogen) Real Time PCR analysis of target promoters using a QuantStudio 12K Flex Real Time PCR machine (Life Technologies, Carlsbad, CA). Accession codes of the genes whose promoter regions were amplified and primers sequences are shown in Supplementary Table 1 .
Bioinformatics analysis of dnA arrays. After initial exploratory analysis of the peak signal data, we chose to use a rank-based approach to compare relative methylation between arrays and time points, as variation in absolute signal intensity between both time points and arrays within the time points was apparent. At least part of this variation may be attributed to the small number of biological replicates per time point (n = 3) used for the arrays. Probe regions were overlapped with the gene annotation regions given by the manufacturer, using the GenomicRanges Bioconductor package (http://www.bioconductor.org/) in R 2.15 (http://cran.r-project.org/). Although we first analyzed together both tracts provided by the array output-that is, one depicting methylation in CpG islands and the other depicting methylation of promoter regions-we also performed a Identification of putative Pcg target motif in the Kiss1 promoter. Using a combination of Transfac analysis (http://www.biobase-international.com/ product/transcription-factor-binding-sites/) and literature search, we examined 3 kb upstream of the rat Kiss1 promoter for several motifs found to be present in PcG target genes, including the core motif for YY1 binding (CCAT), the GAF (GAGAG) and extended MPho (CNGCCATNDNND) motifs, the two BMI1 binding motifs (CCTTCC and GGNNNGNG), and the binding motif for HOTAIR, a long noncoding RNA, recently shown to serve as an anchor for PcG binding to gene promoters 38 (Supplementary Fig. 5a ). As position-weight matrices were not reported for the binding motifs other than HOTAIR, we scanned for occurrences of all other motifs in the promoter using a custom Perl script and the reported consensus sequence. In the case of HOTAIR, we reconstructed the motif reported in ref. 38 on the basis of sequences provided by the laboratory of H.W. Chang (Stanford University), using the MEME tool (http://meme.nbcr.net/meme/) as reported in the reference. Our motif was then loaded as a custom PWM into the TRANSFAC motif discovery tool. We scanned for HOTAIR binding sites using a minimization of total false positive/negative (MinSUM) criteria.
Functional promoter assays. These assays were performed using HEK-293T cells and a luciferase reporter construct containing the 5′ flanking region of the Kiss1 gene, in addition to EED (see below) and/or YY1 expression vectors. Transfection efficiency was normalized by cotransfecting the plasmid CMV-Sport-β-gal (Invitrogen) at 10 ng/ml and determining β-galactosidase activity using the Tropix Galacto Reaction (ABI).
Preparation of eed-expressing lentiviral particles and production of viruses.
To generate lentiviral particles expressing the rat Eed gene (LV-EED), we used a 3rd generation vector plasmid in which the promoter sequences of the 5′ LTR were replaced by the cytomegalovirus (CMV) promoter, resulting in the formation of a heterologous U3 (htU3) promoter 56 (Supplementary Fig. 7a) . The coding region of rat Eed tagged with the human influenza hemagglutinin epitope (HA) for easy detection by western immunoblotting was cloned into the BamHI-EcoRV sites of the plasmid's multiple cloning site. This cDNA is followed by an internal ribosome entry site (IRES) and a cDNA encoding an enhanced green fluorescent protein (eGFP). To enhance transgene expression, we inserted the rat insulin II intron A sequence between the CMV promoter and the Eed cDNA ( Supplementary Fig. 7a) 56 . Infective lentiviral particles were produced as previously described 56 .
western blots. To verify the ability of the LV-EED construct to produce EED, we transfected COS7 cells with the construct using Lipofectamine 2000 (Invitrogen) and lysed the cells 48 h later with 500 µl of freshly prepared RIPA buffer. Antibodies to the HA epitope (Covance, MMS-101R) are described in Supplementary Table 2 ; they were used at a 1:2,000 dilution (overnight at 4 °C) followed by an speciesspecific anti-IgG-HRP antibody (1 h at 25 °C, 1:1,000; Invitrogen). The signal was developed by enhanced chemiluminescence using the Western lightning chemiluminescence substrate (Pierce).
Stereotaxic delivery of lentiviral particles.
To deliver LV particles carrying the Eed transgene to the ARC, we used P26 early juvenile female rats and a procedure previously reported 57 .
Statistics. Quantitative data were analyzed using SigmaPlot 11 software (Systat Software Inc., San Jose, CA). The data were first subjected to a normality test and an equal variance test. Data that passed these two tests were then analyzed by either ANOVA followed by the Student-Newman-Keuls multiple comparison test when comparing several groups or Student's t-test to compare two groups. Because pulsatile GnRH release did not pass the equal variance test, these results were analyzed using the Mann-Whitney rank-sum test. When comparing percentages, groups were subjected to arcsine transformation before statistical analysis to convert them from a binomial to a normal distribution. The sample size was selected based on power analyses performed using the s.d. that we normally observe when measuring the parameters examined in this study and an n = 6 per group. These analyses provide at least 80% (type II error = 0.124) power to detect two effect sizes using either ANOVA or two-sided two-sample t-test with a significance level of 0.05.
